of Tumours of the recommendations for Central Nervous the classification of System (ed 4th). CNS tumours. Lyon, IARC Press, 2016 3. Observational A study of 136 cases of 2012 Sturm D, Witt H, glioblastoma (GBM) Hovestadt V, et al. that identified H3F3A Hotspot mutations in H3F3A and IDH1 and IDH1 molecular define distinct subgroups. epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425-37. 4. Study of Cahill DP, Louis DN, A study into molecular 7 Nov diagnostic Cairncross JG: identification of 2015 accuracy Molecular oligodendroglioma as a background of subcategory of oligodendroglioma: gliomas. The findings 1p/19q, IDH, TERT, provided a foundation CIC and FUBP1. CNS for the consistent Oncol 4:287-94, diagnosis of the 2015 tumour type, for which there is a strong evidence base for effective treatment with radiation and chemotherapy. 5. Observational of actionable 2016 Staedtke V, Dzaye study biomarkers available in ODA, Holdhoff M. Actionable the diagnosis of brain tumours. (i) MGMT Molecular Biomarkers in promoter methylation Primary Brain as a prognostic and Tumors. Trends predictive marker in Cancer. glioblastoma; (ii) 2016;2(7):338-49. codeletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas; (iii) IDH1/2 mutations; and (iv) select associated mutations. 6. Observational Rare Cancers A review of available 2016 study Australia: Just a cancer data Little More Time investigating the Rare Cancers disparities existing for Update Report. incidence, mortality 2016 and survival across the
of Tumours of the Central Nervous System (ed 4th). Lyon, IARC Press, 2016 recommendations for the classification of CNS tumours. 3. Observational Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425-37. A study of 136 cases of glioblastoma (GBM) that identified H3F3A and IDH1 molecular subgroups. 2012 4. Study of diagnostic accuracy Cahill DP, Louis DN, Cairncross JG: Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol 4:287-94, 2015 A study into molecular identification of oligodendroglioma as a subcategory of gliomas. The findings provided a foundation for the consistent diagnosis of the tumour type, for which there is a strong evidence base for effective treatment with radiation and chemotherapy. 7 Nov 2015 5. Observational study Staedtke V, Dzaye ODA, Holdhoff M. Actionable Molecular Biomarkers in Primary Brain Tumors. Trends Cancer. 2016;2(7):338-49. of actionable biomarkers available in the diagnosis of brain tumours. (i) MGMT promoter methylation as a prognostic and predictive marker in glioblastoma; (ii) codeletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas; (iii) IDH1/2 mutations; and (iv) select mutations. 2016 6. Observational study Rare Cancers Australia: Just a Little More Time Rare Cancers Update Report. 2016 A review of available cancer data investigating the disparities existing for incidence, mortality and survival across the 2016 associated
Somatic_Gene_Testing_(Web_AccessibleVersion2).docx